# Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

Ming Kai Lam<sup>1</sup>, MD; Kenneth Tandjung<sup>1</sup>, MD; Hanim Sen<sup>1</sup>, MD; Mounir W.Z. Basalus<sup>1</sup>, MD, PhD; K. Gert van Houwelingen<sup>1</sup>, MD; Martin G. Stoel<sup>1</sup>, MD, PhD; Johannes W. Louwerenburg<sup>1</sup>, MD; Gerard C.M. Linssen<sup>2</sup>, MD, PhD; Salah A.M. Saïd<sup>3</sup>, MD, PhD; Mark B. Nienhuis<sup>4</sup>, MD, PhD; Frits H.A.F. de Man<sup>1</sup>, MD, PhD; Job van der Palen<sup>5,6</sup>, PhD; Clemens von Birgelen<sup>1,7\*</sup>, MD, PhD

1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. Department of Cardiology, Ziekenhuisgroep Twente, Almelo, The Netherlands; 3. Department of Cardiology, Ziekenhuisgroep Twente, Hengelo, The Netherlands; 4. Department of Cardiology, Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands; 5. Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands; 6. Department of Research Methodology, Measurement and Data Analysis, University of Twente, Enschede, The Netherlands; 7. Health Technology and Services Research, MIRA – Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands

#### **KEYWORDS**

- coronary dominance
- percutaneous coronary intervention
- periprocedural myocardial infarction
- TWENTE trial

#### **Abstract**

**Aims:** To investigate the prognostic value of coronary dominance for various adverse clinical events following the implantation of drug-eluting stents.

Methods and results: We assessed two-year follow-up data of 1,387 patients from the randomised TWENTE trial. Based on the origin of the posterior descending coronary artery, coronary circulation was categorised into left and non-left dominance (i.e., right and balanced). Target vessel-related myocardial infarction (MI) was defined according to the updated Academic Research Consortium (ARC) definition (2x upper reference limit of creatine kinase [CK], confirmed by CK-MB elevation), and periprocedural MI (PMI) as MI ≤48 hours following PCI. One hundred and thirty-six patients (9.8%) had left and 1,251 (90.2%) non-left dominance. Target lesions were more frequently located in dominant arteries (p<0.005). Left dominance was associated with more severe calcifications (p=0.006) and more bifurcation lesions (p=0.031). Non-left dominance tended to be less frequent in men (p=0.09). Left coronary dominance was associated with more target vessel-related MI (14 [10.3%] vs. 62 [5.0%], p=0.009). Left dominance independently predicted PMI (adjusted HR 2.19, 95% CI: 1.15-4.15, p=0.017), while no difference in other clinical endpoints was observed between dominance groups.

**Conclusions:** In the population of the TWENTE trial, we observed a higher incidence of periprocedural myocardial infarction in patients who had left coronary dominance.

<sup>\*</sup>Corresponding author: Thoraxcentrum Twente, Department of Cardiology, Haaksbergerstraat 55, 7513 ER Enschede, The Netherlands. E-mail: c.vonbirgelen@mst.nl

### **Abbreviations**

**ARC** Academic Research Consortium

**DES** drug-eluting stents

**LAD** left anterior descending artery

**LCX** left circumflex artery

MACE major adverse cardiac events

MI myocardial infarction

**PCI** percutaneous coronary intervention

**PDA** posterior descending artery

**PMI** periprocedural myocardial infarction

**RCA** right coronary artery

**STEMI** ST-elevation myocardial infarction

**TLF** target lesion failure

TLR target lesion revascularisation

**TVF** target vessel failure

**TVR** target vessel revascularisation

# Introduction

Left coronary artery dominance is a variant of the normal coronary anatomy, in which the left circumflex artery reaches the crux and supplies both posterior descending and posterolateral branches<sup>1,2</sup>. A recent post-mortem analysis showed a decreasing prevalence of left dominance with the increase of age, suggesting a worse prognosis for subjects with this dominance pattern<sup>3</sup>. The database of a registry of patients undergoing cardiac catheterisation for acute coronary syndromes has demonstrated higher all-cause mortality in patients with left dominance<sup>4</sup>. In addition, a non-invasive study with computed tomography coronary angiography screening of the coronary arteries in a heterogeneous group of patients with chest pain (with or without coronary artery disease) showed left dominance to be an independent predictor of non-fatal myocardial infarction (MI) and all-cause mortality<sup>2</sup>.

However, there is limited knowledge about the relation between coronary dominance patterns and the risk of various adverse clinical events that can occur following percutaneous coronary interventions (PCI) with contemporary drug-eluting stents (DES). The aim of this study was to investigate the prognostic value of left dominance in relation to post-PCI outcome – in particular the rate of periprocedural MI (PMI), which in current DES studies has the highest incidence of all adverse clinical events<sup>5-7</sup>. We performed the analyses in patients in the prospective, randomised TWENTE trial<sup>5,8</sup>, which assessed a population of PCI patients with broad inclusion and only few exclusion criteria, treated with second-generation DES<sup>9</sup>.

#### **Methods**

#### STUDY POPULATION

The study assessed patients enrolled in the TWENTE trial (ClinicalTrials.gov NCT01066650), which has previously been described in detail<sup>5,8</sup>. In brief, TWENTE is an investigator-initiated, patient-blinded, randomised non-inferiority study with broad inclusion and limited exclusion criteria in a study population with a majority of complex lesions and "off-label" indications for DES

use. The study was performed between June 2008 and August 2010 at the Thoraxcentrum Twente, Enschede, The Netherlands. Patients with an indication for PCI with DES, who were capable of providing informed consent, were randomised for treatment with one of two types of second-generation DES - Resolute (Medtronic Inc., Minneapolis, MN, USA) or XIENCE V (Abbott Vascular, Santa Clara, CA, USA). There was no limit for lesion length, reference vessel size, and number of target lesions or vessels to be treated. As a consequence, in a high proportion of study patients there was advanced coronary disease requiring treatment of multiple vessels. bifurcation lesions, long lesions, and lesions in small vessels5. A total of 52% of patients presented with an acute coronary syndrome but, as a very recent ST-elevation myocardial infarction (STEMI) was the most important exclusion criterion, patients requiring primary PCI were not enrolled. The TWENTE trial has demonstrated a similar clinical outcome for both DES5. The study was approved by the institutional ethics committee and complied with the Declaration of Helsinki. All patients provided written informed consent. The study population of the present analysis consisted of all TWENTE patients except four patients who withdrew their consent during follow-up.

# ANGIOGRAPHIC ASSESSMENT OF CORONARY ARTERY DOMINANCE

Coronary dominance was classified into left and non-left by two experienced analysts who inspected the coronary angiography of all TWENTE patients. A coronary artery system was classified as right dominant when the PDA originated from the right coronary artery (RCA), while left dominance was defined when the PDA originated from the left circumflex artery (LCX). A balanced dominant coronary system was categorised when the PDA rose from the RCA in combination with a large posterolateral branch originating from the LCX reaching near the posterior interventricular groove<sup>2</sup>. Right and balanced were referred to as non-left dominance. Any potential disagreement between analysts was resolved by jointly inspecting all angiographic runs available in order to achieve consensus.

#### QUANTITATIVE CORONARY ANGIOGRAPHY

Quantitative coronary angiographic analyses were performed offline with the use of edge-detection software (QAngio XA version 7.1; Medis, Leiden, The Netherlands) by angiographic analysts from the Thoraxcentrum Twente<sup>5</sup>.

## FOLLOW-UP AND DEFINITION OF CLINICAL ENDPOINTS

Details of the clinical follow-up have been reported previously<sup>5,8</sup>. In brief, in the TWENTE trial follow-up data were obtained during two-year follow-up after the index procedure. For any events triggered, all available relevant clinical information was gathered. Clinical event adjudication (follow-up information was available for all patients) was performed by a core laboratory and an external independent research organisation (Cardialysis, Rotterdam, The Netherlands). Clinical endpoints were classified according to the

Academic Research Consortium (ARC) definitions<sup>10,11</sup>. Cardiac death was defined as any death due to proximate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia). MI was defined by any creatine kinase concentration of more than double the upper limit of normal with elevated values of a confirmatory cardiac biomarker (creatine kinase myocardial band fraction or troponin), based on the updated ARC definition of MI. Periprocedural MI (PMI) was defined as MI within 48 hours after PCI<sup>10,11</sup>. Further classification of MI and MI location was based on laboratory information, electrocardiogram, and/or clinical data. Laboratory information included determination of creatine kinase before PCI and cardiac markers six to 18 hours after PCI, with subsequent serial measurements in case of relevant biomarker elevation or complaints (97% of the cases had at least one blood sampling performed between 12 and 18 hours after PCI). Stent thrombosis was defined according to ARC as definite or probable.

The composite endpoint of target vessel failure (TVF) was defined as cardiac death, target vessel-related MI, or clinically driven target vessel revascularisation (TVR). Target lesion failure (TLF) was defined as the composite of cardiac death, target vessel-related MI, and clinically indicated target lesion revascularisation (TLR); major adverse cardiac events as the composite of all-cause death, any MI, emergent coronary artery bypass surgery, or clinically indicated TLR; and a patient-oriented composite endpoint as the composite of all-cause mortality, any MI, and any repeat (target and non-target vessel) revascularisation<sup>5</sup>.

#### STATISTICAL ANALYSIS

Categorical data were presented as frequencies and percentages whereas continuous variables were expressed as mean±standard deviation (SD). To assess potential differences in the prevalence of dominance patterns between younger and older patients, age was categorised using the mean of the total population as the cut-off value. The baseline characteristics were compared using the chisquare test or Fisher's exact test for categorical variables and oneway analysis of variance (ANOVA) for continuous variables including age, BMI, minimum reference diameter and total stent length, as the data were distributed normally. The Kruskal-Wallis test (non-parametric data) was used to compare the total number of stents placed between dominance patterns, and results presented as median and interquartile range (IQR). Univariate and Cox regression analysis was performed to assess coronary dominance as an independent predictor with respect to the predefined endpoints. Potential confounding was identified if p-values were <0.10 at univariate analysis of the relations between tested parameter and both dominance and predefined clinical endpoints. A multivariate Cox regression analysis was then performed to adjust for potential confounders. The time to MI was assessed according to the Kaplan-Meier method, in which the log-rank test was applied to compare the coronary dominance patterns. Analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Unless otherwise specified, confidence intervals and p-values were two-sided. A p-value < 0.05 was considered statistically significant.

#### Results

#### PATIENT CHARACTERISTICS

A total of 1,387 patients were analysed, of whom 136 (9.8%) had left dominance and 1,251 (90.2%) non-left dominance, consisting of 1,077 (77.6%) right and 174 (12.5%) balanced dominance. In all 1,387 patients, follow-up data were available. Baseline characteristics are shown in **Table 1**. Male gender tended to be more frequent in the left than in the non-left dominance group (78.7% vs. 71.8%, respectively; p=0.087). There was no difference in the prevalence of dominance patterns between patients aged  $\leq$ 64 and older (p=0.79). Patients with left dominance tended less often to have a previous PCI (p=0.11).

#### ANGIOGRAPHIC AND PROCEDURAL CHARACTERISTICS

Angiographic analysis revealed that target lesions were more frequently located in the dominant artery **(Table 2)**: left and non-left dominance were present in 64.0% vs. 50.8% if target lesions were located in the left anterior descending artery (LAD; p=0.004), 50.7% vs. 29.4% if target lesions were located in the LCX (p<0.001), and 6.6% vs. 39.4% if target lesions were located in the RCA (p<0.001).

The ACC/AHA lesion types did not differ in complexity between dominance groups (p=0.6). Left dominance was associated with more severe lesion calcification (p=0.006), more bifurcation lesions (p=0.031), and showed a trend towards more *de novo* lesions (p=0.079). Between dominance groups, there was no significant difference in minimum reference vessel size, the number of lesions treated, and other procedural details.

#### ADVERSE CLINICAL EVENTS DURING TWO-YEAR FOLLOW-UP

Left dominance was associated with a higher incidence of target vessel MI (p=0.009) **(Table 3)**, in particular non-Q-wave MI (p=0.001) and PMI (p=0.004). For all other adverse cardiac events and composite endpoints, there was no significant difference between dominance groups. Definite or probable stent thrombosis was non-significantly more frequent in patients with left dominance than in non-left dominance (2.2% vs. 1.2%, respectively).

# MULTIVARIATE ANALYSIS OF CORONARY DOMINANCE AND MYOCARDIAL INFARCTION

Severe lesion calcification and at least one bifurcated lesion were considered as potential confounders and were therefore included as covariates in a multivariate model. Using the largest group with non-left dominance as a reference, left coronary dominance was shown to be a significant independent predictor of target vessel MI (adjusted HR 1.88, 95% CI: 1.05-3.37, p=0.034) - mainly non-Q-wave MI (adjusted HR 2.35, 95% CI: 1.26-4.36, p=0.007) and PMI (adjusted HR 2.19, 95% CI: 1.15-4.15, p=0.017). In addition, severe lesion calcification and at least one bifurcated lesion were independent predictors for target vessel MI (adjusted HR 2.16, 95% CI: 1.35-3.46, p=0.001, adjusted HR 1.60, 95% CI: 1.00-2.55, p=0.048, respectively) and for non-Q-wave MI (adjusted HR 1.81, 95% CI: 1.05-3.14, p=0.034, adjusted HR 2.00, 95% CI: 1.19-3.56,

Table 1. Patient characteristics in left and non-left coronary dominance.


		Total population (n=1,387)	Left (n=136)	Non-left (n=1,251)	<i>p</i> -value
Age	All patients (years)	64.3 (10.6)	64.6 (10.7)	64.2 (10.5)	0.685
	Equal to or younger than 64 years	688 (49.6)	66 (48.5)	622 (49.7)	0.792
	Older than 64 years	699 (50.4)	70 (51.5)	629 (50.3)	
Gender (male) (%)		1,005 (72.5)	107 (78.7)	898 (71.8)	0.087
Clinical risk factor	Diabetes mellitus (any)	299 (21.6)	29 (21.3)	270 (21.6)	0.944
	Hypercholesterolaemia	801/1,353 (59.2)	78/132 (59.1)	723/1,221 (59.2)	0.978
	Arterial hypertension	771 (55.6)	75 (55.1)	696 (55.6)	0.913
	Family history of CAD	737 (53.1)	65 (47.8)	672 (53.7)	0.189
	Current smoking	340 (24.5)	33 (24.3)	307 (24.5)	0.943
	BMI (kg/m³)	27.7±4.0 (1,186)	28.1±3.8 (118)	27.7±4.0 (1,068)	0.299
Known vascular disease (%)	Previous MI (any)	450 (32.4)	45 (33.1)	405 (32.4)	0.866
	Previous PCI	287 (20.7)	21 (15.4)	266 (21.3)	0.111
	Previous CABG	148 (10.7)	14 (10.3)	134 (10.7)	0.881
	Previous heart valve surgery	4/1,368 (0.3)	0/135 (0.0)	4/1,233 (0.3)	1.000
	Previous stroke	43 (3.1)	6 (4.4)	37 (3.0)	0.304
	Previous TIA	70 (5.0)	8 (5.9)	62 (5.0)	0.639
Clinical indication	Stable angina pectoris	672 (48.4)	73 (53.7)	599 (47.9)	0.436
	Unstable angina pectoris	324 (23.4)	29 (21.3)	295 (23.6)	
	Non-ST-elevation MI	391 (28.2)	34 (25.0)	357 (28.5)	
Medication usage	Acetylsalicylic acid	1,376 (99.2)	135 (99.3)	1,241 (99.2)	1.000
	Clopidogrel	1,387 (100)	136 (100)	1,251 (100)	
	Statins	1,191 (85.9)	111 (81.6)	1,080 (86.3)	0.134
	Beta-blocker	1,145 (82.6)	116 (85.3)	1,029 (82.3)	0.375
	ACE inhibitor	394 (28.4)	39 (28.7)	355 (28.4)	0.941
Left ventricular ejection fraction <30%*		32/1,048 (3.1)	5/95 (5.3)	27/953 (2.8)	0.202

Values are n (%) or mean±SD. \*Left ventricular ejection fraction assessed with ultrasound, magnetic resonance imaging or left ventricular angiography. BMI: body mass index; CABG: coronary artery bypass grafting; CAD: coronary artery disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; TIA: transient ischaemic attack

p=0.009, respectively). For PMI, severe lesion calcification tended to predict PMI (adjusted HR 1.75, 95% CI: 0.99-3.07, p=0.051) and at least one bifurcated lesion was an independent predictor (adjusted HR 2.13, 95% CI: 1.26-3.59, p=0.005). Kaplan-Meier MI-free survival analysis stratified for the dominance groups demonstrated a higher incidence of MI in patients with left dominance (p=0.009) (Figure 1). The MI occurred most frequently as PMI – that is, within the first two days, after which both survival curves showed hardly any change.

#### **Discussion**

Within the 1,387 patients of the prospective randomised TWENTE trial, left coronary dominance was an independent predictor of PMI following the implantation of contemporary second-generation DES and was associated with a higher MI rate at two-year follow-up. The relation between left coronary dominance and both MI and PMI remained after correcting for confounders, including severe lesion calcification and at least one bifurcated lesion. Despite significant differences in PMI and MI rates at two-year follow-up, no



**Figure 1.** *MI-free survival in patients with non-left and left coronary dominance (2-year follow-up).* 

Table 2. Baseline lesion and angiographic characteristics in patients with left and non-left coronary dominance.

		Total (n=1,387)	Left (n=136)	Non-left (n=1,251)	<i>p</i> -value
Target lesion coronary artery	Left main stem	52 (3.7)	7 (5.1)	45 (3.6)	0.366
	Left anterior descending artery (LAD)	723 (52.1)	87 (64.0)	636 (50.8)	0.004
	Left circumflex artery (LCX)	437 (31.5)	69 (50.7)	368 (29.4)	<0.001
	Right coronary artery (RCA)	502 (36.2)	9 (6.6)	493 (39.4)	<0.001
	Bypass graft	41 (3.0)	2 (1.5)	39 (3.1)	0.423
ACC/AHA lesion class	A	91 (6.6)	12 (8.8)	79 (6.3)	0.591
	B1	294 (21.2)	27 (19.9)	267 (21.3)	
	B2	428 (30.9)	45 (33.1)	383 (30.6)	
	С	574 (41.4)	52 (38.2)	522 (41.7)	
Type of lesions	De novo lesions only*	1,284 (92.6)	131 (96.3)	1,153 (92.2)	0.079
	At least one chronic total occlusion	95 (6.8)	9 (6.6)	86 (6.9)	0.910
	At least one in-stent restenosis	68 (4.9)	3 (2.2)	65 (5.2)	0.125
	At least one bifurcation lesion	362 (26.1)	46 (33.8)	316 (25.3)	0.031
	At least one aorto-ostial lesion	152 (11.0)	8 (5.9)	144 (11.5)	0.046
	At least one severe calcification	274 (19.8)	39 (28.7)	235 (18.8)	0.006
	At least one thrombus present#	61 (4.4)	4 (2.9)	57 (4.6)	0.510
	At least one total occlusion	184 (13.3)	16 (11.8)	168 (13.4)	0.587
Total number of lesions treated/patient	1 lesion treated	856 (61.7)	84 (61.8)	772 (61.7)	0.913
	2 lesions treated	391 (28.2)	37 (27.2)	354 (28.3)	
	3 or more lesions treated	140 (10.1)	15 (11.0)	125 (10.0)	
Multivessel treatment		334 (24.1)	34 (25.0)	300 (24.0)	0.792
PCI-related	Minimum reference diameter (mm)	2.6±0.6	2.5±0.6	2.6±0.6	0.198
characteristics	Total number of stents	2.0 (1.0-3.0)	2.0 (1.0-3.0)	2.0 (1.0-3.0)	0.591
	Total stent length (mm)	40.98±26.9	39.2±24.1	41.4±27.1	0.419
	At least one direct stenting	662 (47.7)	62 (45.6)	517 (48.0)	0.868
	At least one stent post-dilation	1,218 (87.8)	121 (89.0)	948 (88.0)	0.665
	Maximal inflation pressure (atm)	15.9±2.6	15.9±2.8	15.9±2.6	0.898

Values are n (%), mean±SD or median (IQR). \*Including chronic total occlusion but not grafts and in-stent restenosis. \*Thrombus triggering use of thrombus aspiration catheters. ACC: American College of Cardiology; AHA; American Heart Association

difference in other clinical endpoints was observed between dominance groups. While the present study adds novel information on the relation between coronary anatomy and clinical outcome following PCI, the limited power of the analysis requires that the findings of this study should be considered as hypothesis-generating.

#### PERIPROCEDURAL MYOCARDIAL INFARCTION

This study demonstrated that left dominance is associated with a 2.2-times higher risk of PMI. The relation between anatomical features such as the coronary distribution pattern and PMI had not been assessed until now. In DES trials, the MI rate is a component of several combined clinical endpoints; the PMI rate represents the vast majority of the MI rate which is an endpoint in both stent trials and pathophysiological studies<sup>12-15</sup>. The mechanism underlying the increased PMI risk in left coronary dominance is still unclear. Previous studies have demonstrated that complex plaque morphologies and greater atheroma volumes bear a greater risk of significant plaque (micro)embolisation which can lead to microvascular

injury<sup>16-20</sup>. Furthermore, PCI-related (stent-induced) closure of epicardial arteries may lead to blood flow reduction or occlusion in side branches with subsequent myocardial injury<sup>16</sup>. Both microembolisation and stent-induced closure of very small side branches may not be visible on the angiogram but can lead to cardiac marker release and PMI.

#### CLINICAL OUTCOME

A few registries and studies have shown relations between left dominance and inferior clinical outcome<sup>2-4</sup>, but the patient populations of these studies differed significantly from that of the TWENTE trial<sup>5</sup>. A recently published post-mortem angiography study showed that the prevalence of left and balanced dominance decreased with increasing age<sup>3</sup>, while we found no relation between age and dominance pattern in the population of TWENTE trial patients, who were on average at a younger age (being normally distributed) than the population of the aforementioned post-mortem study that also comprised a wider age range (with non-Gaussian distribution).

Table 3. 2-year clinical outcome in patients with left and non-left coronary dominance.

		Total (n=1,387)	Left (n=136)	Non-left (n=1,251)	<i>p</i> -value
Death	Any cause	62 (4.5)	8 (5.9)	54 (4.3)	0.401
	Cardiac cause	30 (2.2)	4 (2.9)	26 (2.1)	0.528
Myocardial infarction	Any	79 (5.7)	14 (10.3)	65 (5.2)	0.015
	Target-vessel	76 (5.5)	14 (10.3)	62 (5.0)	0.009
	Q-wave	17 (1.2)	1 (0.7)	16 (1.3)	1.000
	Non-Q-wave	59 (4.3)	13 (9.6)	46 (3.7)	0.001
Periprocedural MI		57 (4.1)	12 (8.8)	45 (3.6)	0.004
Major adverse cardiac events*		172 (12.4)	22 (16.2)	150 (12.0)	0.160
Patient-oriented composite endpoint#		232 (16.7)	28 (20.6)	204 (16.3)	0.204
Clinically indicated TVR	Any	74 (5.3)	5 (6.8)	69 (5.5)	0.365
	Percutaneous	60 (4.3)	3 (2.2)	57 (4.6)	0.201
	Surgical	16 (1.2)	2 (1.5)	14 (1.1)	0.665
Clinically indicated TLR	Any	52 (3.7)	3 (2.2)	49 (3.9)	0.318
	Percutaneous	41 (3.0)	2 (1.5)	39 (3.1)	0.423
	Surgical	13 (0.9)	1 (0.7)	12 (1.0)	1.000
Target lesion failure		141 (10.2)	18 (13.2)	123 (9.8)	0.212
Target vessel failure		155 (11.2)	19 (14.0)	136 (10.9)	0.276
Stent thrombosis (definite or probable)		18 (1.3)	3 (2.2)	15 (1.2)	0.410

Values are n (%). \*Major adverse cardiac events are a composite of all-cause death, any myocardial infarction (MI), emergent coronary artery bypass surgery, or clinically indicated target lesion revascularisation (TLR). #Patient-oriented composite endpoint is a composite of endpoint af all-cause death, any MI, or any revascularisation. TVR: target vessel revascularisation

In a heterogeneous group of patients with chest pain, computed tomography coronary angiographic screening revealed left dominance to be an independent predictor of non-fatal MI and all-cause mortality<sup>2</sup>. In addition, in a registry of patients with acute coronary syndromes, left dominance was associated with higher all-cause mortality<sup>4</sup>.

Our present study in a population of PCI patients with broad inclusion and only few exclusion criteria, consisting almost equally of patients with acute coronary syndromes and stable angina<sup>5,9</sup>, adds further information on the prognostic impact of left coronary dominance with regard to various aspects of clinical outcome following PCI. Although we did not observe an inferior outcome in terms of higher mortality, treatment failure, or major adverse cardiac events, we found an independent association between left dominance and PMI which, in the presence of major cardiac marker release, may be related to increased mortality<sup>16,21-24</sup>. Furthermore, in patients with left dominance we observed more bifurcated and severely calcified coronary lesions, lesions with characteristics that are known to be associated with inferior clinical outcome25. While our data may not have direct clinical implications, our findings suggest that further research may be warranted to clarify the role of coronary dominance. Left coronary dominance in the presence of left main disease and a proximal LAD stenosis may sometimes lead to surgical revascularisation or, if PCI is performed, may trigger a more aggressive pharmacological antiplatelet and/or anticoagulation therapy, as the

occlusion of a dominant CX artery may induce serious complications. This impact of a dominant circumflex coronary artery on PCI procedural risk is also reflected in the SYNTAX score<sup>26,27</sup>.

#### Limitations

The present study is a non-pre-specified post hoc analysis of the TWENTE trial with two-year clinical follow-up. Nevertheless, any prolongation of follow-up would have had no effect on the difference in PMI between dominance groups (PMI may only occur during the first 48 hours after PCI), which was the main finding of this study. In addition, none of the other clinical outcome parameters (i.e., other than MI and PMI) showed a trend towards significant difference between coronary dominance groups. While the adjudication of MI was performed according to the ARC definitions, we did not stratify events for different levels of CK-MB elevation (e.g., >5x or >10x the upper reference limit of CK-MB). In future assessments of this issue, it may be valuable to stratify the CK-MB value to certain levels in order to define the severity of MI better. In addition, we cannot completely exclude that during follow-up a subclinical MI might have been missed, especially if it did not lead to hospitalisation, revascularisation by PCI or CABG, and/or if ECG changes were not recognisable. Because of the limited power of the present post hoc analysis, no definite conclusion can be drawn and findings should be considered hypothesis-generating. Nevertheless, the current findings add novel information on the relation between coronary anatomy and clinical outcome following PCI.

#### Conclusion

In the population of the TWENTE trial, we observed a higher incidence of periprocedural myocardial infarction in patients who had left coronary dominance.

# Impact on daily practice

Revascularisation of a significant lesion in a left-dominant coronary system may be associated with an increased risk of periprocedural myocardial infarction. In such lesions, additional measures to prevent this adverse event may be considered (e.g., more aggressive pharmacological therapy). In the presence of significant left main and proximal LAD disease with unfavourable anatomies, left coronary dominance may sometimes suggest serious consideration of surgical coronary revascularisation.

#### Conflict of interest statement

C. von Birgelen was consultant to, and has received lecture fees or travel expenses from Abbott Vascular, Boston Scientific and Medtronic; he received travel expenses from Biotronik and a lecture fee from MSD. The institution has received research grants from Abbott Vascular, Biotronik, Boston Scientific and Medtronic. The other authors have no conflicts of interest to declare.

## References

- 1. Higgins CB, Wexler L. Reversal of dominance of the coronary arterial system in isolated aortic stenosis and bicuspid aortic valve. *Circulation*. 1975;52:292-6.
- 2. Veltman CE, de Graaf FR, Schuijf JD, van Werkhoven JM, Jukema JW, Kaufmann PA, Pazhenkottil AP, Kroft LJ, Boersma E, Bax JJ, Schalij MJ, van der Wall EE. Prognostic value of coronary vessel dominance in relation to significant coronary artery disease determined with non-invasive computed tomography coronary angiography. *Eur Heart J.* 2012;33:1367-77.
- 3. Knaapen M, Koch AH, Koch C, Koch KT, Li X, van Rooij PC, Tijssen JG, Peters RJ, van der Wal AC, Damman P, de Winter RJ. Prevalence of left and balanced coronary arterial dominance decreases with increasing age of patients at autopsy. A postmortem coronary angiograms study. *Cardiovasc Pathol.* 2013;22:49-53.
- 4. Goldberg A, Southern DA, Galbraith PD, Traboulsi M, Knudtson ML, Ghali WA; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Coronary dominance and prognosis of patients with acute coronary syndrome. *Am Heart J.* 2007;154:1116-22.
- 5. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. *J Am Coll Cardiol.* 2012;59:1350-61.
- 6. Tandjung K, van Houwelingen KG, Jansen H, Basalus MW, Sen H, Löwik MM, Stoel MG, Louwerenburg JH, de Man FH,

- Linssen GC, Nijhuis R, Nienhuis MB, van der Palen J, Stolk RP, von Birgelen C. Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial). *Am J Cardiol*. 2012;110:1561-7.
- 7. Tandjung K, Basalus MW, Muurman E, Louwerenburg HW, van Houwelingen KG, Stoel MG, de Man FH, Jansen H, Huisman J, Linssen GC, Droste HT, Nienhuis MB, von Birgelen C. Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents. *Catheter Cardiovasc Interv.* 2012;80:524-30.
- 8. Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, Saïd SA, Nienhuis MB, Löwik MM, Verhorst PM, van der Palen J, von Birgelen C. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. *J Am Coll Cardiol*. 2013;61: 2406-16.
- 9. Sen H, Tandjung K, Basalus MW, Löwik MM, van Houwelingen GK, Stoel MG, Louwerenburg HW, de Man FH, Linssen GC, Nijhuis R, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C. Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents. *EuroIntervention*. 2012;8:664-71.
- 10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344-51.
- 11. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. *EuroIntervention*. 2010;5:871-4.
- 12. Wang TY, Peterson ED, Dai D, Anderson HV, Rao SV, Brindis RG, Roe MT; National Cardiovascular Data Registry. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). *J Am Coll Cardiol*. 2008;51:2068-74.
- 13. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J, Schmermund A, Wieneke H, von Birgelen C, Eggebrecht H, Baumgart D, Heusch G, Erbel R. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. *Circulation*. 2001;103:2339-45.
- 14. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, Erbel R. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. *Circulation*. 2002;106:2180-3.

- 15. Böse D, von Birgelen C, Zhou XY, Schmermund A, Philipp S, Sack S, Konorza T, Möhlenkamp S, Leineweber K, Kleinbongard P, Wijns W, Heusch G, Erbel R. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. *Basic Res Cardiol.* 2008;103:587-97.
- 16. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. *N Engl J Med.* 2011;364:453-64.
- 17. Goldstein JA. Periprocedural myocardial infarction: it's the plaque, not the stent. *Catheter Cardiovasc Interv.* 2012;80:531-2.
- 18. Hong YJ, Mintz GS, Kim SW, Lee SY, Okabe T, Pichard AD, Satler LF, Waksman R, Kent KM, Suddath WO, Weissman NJ. Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. *JACC Cardiovasc Imaging*. 2009;2:458-68.
- 19. Uetani T, Amano T, Ando H, Yokoi K, Arai K, Kato M, Marui N, Nanki M, Matsubara T, Ishii H, Izawa H, Murohara T. The correlation between lipid volume in the target lesion, measured by integrated backscatter intravascular ultrasound, and post-procedural myocardial infarction in patients with elective stent implantation. *Eur Heart J.* 2008;29:1714-20.
- 20. Watabe H, Sato A, Akiyama D, Kakefuda Y, Adachi T, Ojima E, Hoshi T, Murakoshi N, Ishizu T, Seo Y, Aonuma K. Impact of coronary plaque composition on cardiac troponin elevation after percutaneous coronary intervention in stable angina pectoris: a computed tomography analysis. *J Am Coll Cardiol*. 2012;59:1881-8.
- 21. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous

- coronary intervention: A meta-analysis. *Catheter Cardiovasc Interv.* 2008;71:318-24.
- 22. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. *J Am Coll Cardiol.* 2006;48:1765-70.
- 23. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. *J Am Coll Cardiol*. 2003;42:1406-11.
- 24. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. *Circulation*. 2002;106:1205-10.
- 25. Ramakrishna G, Miller TD, Breen JF, Araoz PA, Hodge DO, Gibbons RJ. Relationship and prognostic value of coronary artery calcification by electron beam computed tomography to stress-induced ischemia by single photon emission computed tomography. *Am Heart J.* 2007;153:807-14.
- 26. Leaman DM, Brower RW, Meester GT, Serruys P, van den Brand M. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. *Circulation*. 1981;63:285-99.
- 27. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention*. 2005;1:219-27.